News

From Approvals to Appointments: Who Pays for Psychedelic Therapy, and How?

  • Two to Four Months From Approval to First Dose, Says Compass
  • Inside an Interventional Psychiatry Clinic
  • Medicaid Is Where Scale Lies, Says PMHAA’s Shah
  • The Employer Route: Faster Access via Self-Funded Plans?
  • The ‘Black Box’ of Dosing Day
  • Will Patient Support Programs Deliver?
  • Where Were the Commercial Payors?

At The Psychedelic Healthcare Forum, co-hosted by Psychedelic Alpha and Horizons in New York on October 15th, we dedicated a significant portion of our afternoon programming to a question that has loomed large in the field of late: Once a psychedelic is approved, how does it actually reach patients, and who pays?

The block was moderated by Jazz Glastra, Senior Director at BrainFutures, who framed the journey from approval to access as “a massive collective action problem”. It comprised two sets of short talks followed by a roundtable, and the speakers were:

  • Lori Englebert, Chief Commercial Officer, Compass Pathways
  • Jeffrey Zabinski, Director of Interventional Psychiatry, Columbia University Irving Medical Center
  • Tanya Brara Shah, Strategic Advisor, Psychedelic Mental Health Access Alliance
  • Lee Lewis, Chief Strategy Officer, Health Transformation Alliance

Here, we share some key takeaways.

Two to Four Months From Approval to First Dose, Says Compass

Compass’ Lori Englebert opened by walking through what needs to happen following FDA approval in order to reach the first patients.

At the time of the Forum, Compass was in the midst of a rolling submission for its COMP360 psilocybin in treatment-resistant depression (TRD), and anticipating approval and launch in the first half of next year. The company has since completed the submission of its new drug application.

Englebert was keen to emphasise that part of her job is managing the expectations of patients and providers.

As regular readers will be aware, following FDA approval DEA must then reschedule the drug, a process that conventionally takes around ninety days. April’s executive order was intended to encourage the steps involved to happen sooner, Englebert noted, but “we actually don’t know how long it’s going to take for the DEA to reschedule”...

Join Today

Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and research.

Monthly $20 Annually $200
  • Regular Bulletins featuring news, analysis, and research
  • Articles and deep dives across psychedelic drug development, policy, and research
  • Exclusive interviews with researchers, executives, and policymakers
  • Bespoke resources and tools including the Psychedelic Bill Tracker
  • Quarterly video briefings and slide decks

Join Today

Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and research.

Monthly $20 Annually $200

Subscribe to our
free newsletter


By signing up, you agree to our privacy policy. You can unsubscribe at any time.

Learn More About

Group, team &
corporate plans


Aside from group pricing, we also offer bespoke reports and regular briefings. Get in touch to discuss.